{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T05:12:29Z","timestamp":1769317949406,"version":"3.49.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA16065"],"award-info":[{"award-number":["R01DA16065"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37DA013806"],"award-info":[{"award-number":["R37DA013806"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01DA036935"],"award-info":[{"award-number":["U01DA036935"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24DA034621"],"award-info":[{"award-number":["K24DA034621"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23DA041294"],"award-info":[{"award-number":["K23DA041294"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Johns Hopkins Institute for Clinical and Translational Research"},{"name":"Center for Clinical Data Analytics","award":["UL1 TR001079"],"award-info":[{"award-number":["UL1 TR001079"]}]},{"DOI":"10.13039\/100017035","name":"Johns Hopkins Center for AIDS Research","doi-asserted-by":"publisher","award":["P30AI094189"],"award-info":[{"award-number":["P30AI094189"]}],"id":[{"id":"10.13039\/100017035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Eliminating hepatitis C virus (HCV) will require effective treatment delivery to persons with substance use disorders (SUDs). We evaluated the relationship between ledipasvir\/sofosbuvir treatment persistence (receiving 84 tablets), adherence, and sustained virologic response (SVR) in persons with human immunodeficiency virus (HIV)\/HCV coinfection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Of the 144 participants with HIV\/HCV and SUDs, 110 initiated a 12-week treatment course under 1 of 3 conditions (usual care, peer mentors, and cash incentives). We used self-report, pharmacy pill counts, and expected date of refill to examine adherence. Persistent participants were categorized as high adherence (taking \u226590% of doses) or low adherence (taking &amp;lt;90% of doses).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Most participants persisted on treatment after initiation (n = 105), with 95% (n = 100) achieving SVR. One third (34%) of participants had moderate\/heavy alcohol use by the biomarker phosphatidylethanol ([Peth] \u226550 ng\/mL), and 44% had urine toxicology positive for cocaine or heroin at enrollment. The proportion of persons with high adherence was 72% (n = 76), and the proportion of persons with low adherence was 28%. Although low adherence was associated with moderate\/heavy alcohol use by PEth (relative risk = 2.77; 95% confidence interval, 1.50\u20135.12), SVR did not vary according to adherence (P = .702), and most participants (97%) with low adherence achieved SVR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Treatment persistence led to high SVR rates among persons with HIV\/HCV, despite imperfect adherence and SUDs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiab477","type":"journal-article","created":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T04:19:17Z","timestamp":1631938757000},"page":"903-911","source":"Crossref","is-referenced-by-count":6,"title":["Nonadherence to Ledipasvir\/Sofosbuvir Did Not Predict Sustained Virologic Response in a Randomized Controlled Trial of Human Immunodeficiency Virus\/Hepatitis C Virus Coinfected Persons Who Use Drugs"],"prefix":"10.1093","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4552-2585","authenticated-orcid":false,"given":"Kathleen M","family":"Ward","sequence":"first","affiliation":[{"name":"Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2321-2295","authenticated-orcid":false,"given":"Oluwaseun","family":"Falade-Nwulia","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juhi","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine G","family":"Sutcliffe","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherilyn","family":"Brinkley","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taryn","family":"Haselhuhn","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Katz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayla","family":"Herne","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian","family":"Arteaga","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti H","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Latkin","sequence":"additional","affiliation":[{"name":"Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K","family":"Brooner","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S","family":"Sulkowski","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,9,20]]},"reference":[{"key":"2022030208291363600_CIT0001","volume-title":"Global hepatitis report, 2017","year":"2017"},{"key":"2022030208291363600_CIT0002","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","article-title":"Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis","volume":"16","author":"Platt","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2022030208291363600_CIT0003","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cld.2005.05.003","article-title":"Natural history of hepatitis C","volume":"9","author":"Thomas","year":"2005","journal-title":"Clin Liver Dis"},{"key":"2022030208291363600_CIT0004","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J Hepatol"},{"key":"2022030208291363600_CIT0005","author":"AASLD-IDSA."},{"key":"2022030208291363600_CIT0006","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"European Association for the Study of the Liver.","year":"2018","journal-title":"J Hepatol"},{"key":"2022030208291363600_CIT0007","doi-asserted-by":"crossref","first-page":"ofy048","DOI":"10.1093\/ofid\/ofy048","article-title":"Hepatitis C treatment outcomes for people who inject drugs treated in an accessible","volume":"5","author":"Eckhardt","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2022030208291363600_CIT0008","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/cid\/ciaa105","article-title":"Concurrent initiation of hepatitis C and opioid use disorder treatment in people who inject drugs","volume":"71","author":"Rosenthal","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022030208291363600_CIT0009","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1093\/cid\/ciz696","article-title":"Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis","volume":"70","author":"Graf","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022030208291363600_CIT0010","doi-asserted-by":"crossref","first-page":"e102883","DOI":"10.1371\/journal.pone.0102883","article-title":"The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care","volume":"9","author":"Cachay","year":"2014","journal-title":"PLoS One"},{"key":"2022030208291363600_CIT0011","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1477-7517-10-7","article-title":"Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors","volume":"10","author":"Harris","year":"2013","journal-title":"Harm Reduct J"},{"key":"2022030208291363600_CIT0012","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","article-title":"Strategies used by people who inject drugs to avoid stigma in healthcare settings","volume":"198","author":"Biancarelli","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"2022030208291363600_CIT0013","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1177\/0956462417725462","article-title":"Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection","volume":"29","author":"Allyn","year":"2018","journal-title":"Int J STD AIDS"},{"key":"2022030208291363600_CIT0014","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3109\/10826084.2016.1161054","article-title":"Clinicians\u2019 views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs","volume":"51","author":"Asher","year":"2016","journal-title":"Subst Use Misuse"},{"key":"2022030208291363600_CIT0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugpo.2018.08.013","article-title":"Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study","volume":"62","author":"Cunningham","year":"2018","journal-title":"Int J Drug Policy"},{"key":"2022030208291363600_CIT0016","doi-asserted-by":"crossref","first-page":"ofz166","DOI":"10.1093\/ofid\/ofz166","article-title":"A randomized controlled trial of cash incentives or peer support to increase HCV treatment for persons with HIV who use drugs: the CHAMPS study","volume":"6","author":"Ward","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2022030208291363600_CIT0017","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann Intern Med"},{"key":"2022030208291363600_CIT0018","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.drugpo.2017.05.025","article-title":"Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada","volume":"47","author":"Mason","year":"2017","journal-title":"Int J Drug Policy"},{"key":"2022030208291363600_CIT0019","first-page":"ofaa418","article-title":"The causal effect of opioid agonist treatment on adherence to direct-acting antiviral treatment for hepatitis C virus","volume":"7","author":"Min","year":"2020","journal-title":"Open"},{"key":"2022030208291363600_CIT0020","doi-asserted-by":"crossref","first-page":"103135","DOI":"10.1016\/j.drugpo.2021.103135","article-title":"High HCV cure rates among people who inject drugs and have suboptimal adherence: a patient-centered approach to HCV models of care","volume":"93","author":"Norton","year":"2021","journal-title":"Int J Drug Policy"},{"key":"2022030208291363600_CIT0021","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1093\/cid\/ciz1089","article-title":"Adherence to once-daily and twice-daily direct-acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy","volume":"71","author":"Cunningham","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022030208291363600_CIT0022","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1360-0443.1997.tb03652.x","article-title":"The Alcohol Use Disorders Identification Test (AUDIT) as a screen for at-risk drinking in primary care patients of different racial\/ethnic backgrounds","volume":"92","author":"Volk","year":"1997","journal-title":"Addiction"},{"key":"2022030208291363600_CIT0023","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/QAI.0000000000001588","article-title":"Alcohol and mortality: combining self-reported (AUDIT-C) and biomarker detected (PEth) alcohol measures among HIV infected and uninfected","volume":"77","author":"Eyawo","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022030208291363600_CIT0024","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0738-3991(01)00219-1","article-title":"Patient adherence to HIV medication regimens: a review of published and abstract reports","volume":"46","author":"Fogarty","year":"2002","journal-title":"Patient Educ Couns"},{"key":"2022030208291363600_CIT0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2036.2009.04004.x","article-title":"Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research","volume":"30","author":"Weiss","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2022030208291363600_CIT0026","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1471-2334-14-203","article-title":"Factors influencing adherence in hepatitis-C infected patients: a systematic review","volume":"14","author":"Mathes","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2022030208291363600_CIT0027","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s10461-011-9942-x","article-title":"Adherence to highly active antiretroviral therapy (HAART): a meta-analysis","volume":"15","author":"Ortego","year":"2011","journal-title":"AIDS Behav"},{"key":"2022030208291363600_CIT0028","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/add.13173","article-title":"Declining and rebounding unhealthy alcohol consumption during the first year of HIV care in rural Uganda, using phosphatidylethanol to augment self-report","volume":"111","author":"Hahn","year":"2016","journal-title":"Addiction"},{"key":"2022030208291363600_CIT0029","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrgastro.2017.106","article-title":"Direct-acting antiviral agents for HCV infection affecting people who inject drugs","volume":"14","author":"Grebely","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022030208291363600_CIT0030","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.drugpo.2017.07.021","article-title":"High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic","volume":"47","author":"Norton","year":"2017","journal-title":"Int J Drug Policy"},{"key":"2022030208291363600_CIT0031","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.drugpo.2015.08.008","article-title":"Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program","volume":"26","author":"Litwin","year":"2015","journal-title":"Int J Drug Policy"},{"key":"2022030208291363600_CIT0032","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S2468-1253(20)30120-5","article-title":"Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial","volume":"5","author":"Radley","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2022030208291363600_CIT0033","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1089\/apc.2010.0142","article-title":"Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration","volume":"24","author":"Swan","year":"2010","journal-title":"AIDS Patient Care STDS"},{"key":"2022030208291363600_CIT0034","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1093\/cid\/cit302","article-title":"Recommendations for the management of hepatitis C virus infection among people who inject drugs","volume":"57","author":"Robaeys","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2022030208291363600_CIT0035","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jvh.13251","article-title":"Unreported alcohol use was common but did not impact hepatitis C cure in HIV-infected persons who use drugs","volume":"27","author":"Irvin","year":"2020","journal-title":"J Viral Hepat"},{"key":"2022030208291363600_CIT0036","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/cid\/ciaa105","article-title":"Concurrent initiation of hepatitis C and opioid use disorder treatment in people who inject drugs","volume":"71","author":"Rosenthal","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022030208291363600_CIT0037","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/cid\/cis1007","article-title":"Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis","volume":"56","author":"Dimova","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2022030208291363600_CIT0038","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/jvh.13175","article-title":"Treatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infection","volume":"26","author":"Read","year":"2019","journal-title":"J Viral Hepat"},{"key":"2022030208291363600_CIT0039","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jsat.2017.01.015","article-title":"Retention in buprenorphine treatment is associated with improved HCV care outcomes","volume":"75","author":"Norton","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"2022030208291363600_CIT0040","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1186\/s12913-019-4635-7","article-title":"A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments","volume":"19","author":"Radley","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"2022030208291363600_CIT0041","volume-title":"Health","author":"Glanz","year":"2008","edition":"4th ed"},{"key":"2022030208291363600_CIT0042","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/apc.2009.0288","article-title":"Trust in physicians and racial disparities in HIV care","volume":"24","author":"Saha","year":"2010","journal-title":"AIDS Patient Care STDS"},{"key":"2022030208291363600_CIT0043","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1525-1497.2006.00396.x","article-title":"Distrust of the health care system and self-reported health in the United States","volume":"21","author":"Armstrong","year":"2006","journal-title":"J Gen Intern Med"},{"key":"2022030208291363600_CIT0044","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/j.1525-1497.2004.30418.x","article-title":"Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection","volume":"19","author":"Schneider","year":"2004","journal-title":"J Gen Intern Med"},{"key":"2022030208291363600_CIT0045","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1177\/1359105314551950","article-title":"Medical mistrust is related to lower longitudinal medication adherence among African-American males with HIV","volume":"21","author":"Dale","year":"2016","journal-title":"J Health Psychol"},{"key":"2022030208291363600_CIT0046","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/08870446.2017.1324969","article-title":"The differences between medical trust and mistrust and their respective influences on medication beliefs and ART adherence among African-Americans living with HIV","volume":"32","author":"Pellowski","year":"2017","journal-title":"Psychol Health"},{"key":"2022030208291363600_CIT0047","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1353\/hpu.2012.0006","article-title":"Trust in primary care providers and antiretroviral adherence in an urban HIV clinic","volume":"23","author":"Blackstock","year":"2012","journal-title":"J Health Care Poor Underserved"},{"key":"2022030208291363600_CIT0048","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/A:1009503320498","article-title":"Measuring adherence among HIV-infected persons: is MEMS consummate technology?","volume":"5","author":"Samet","year":"2001","journal-title":"AIDS Behav"},{"key":"2022030208291363600_CIT0049","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/apt.15707","article-title":"Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence","volume":"51","author":"Sulkowski","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2022030208291363600_CIT0050","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/liv.14266","article-title":"Adherence to pan-genotypic glecaprevir\/pibrentasvir and efficacy in HCV-infected patients: a pooled analysis of clinical trials","volume":"40","author":"Brown","year":"2020","journal-title":"Liver Int"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab477\/40855833\/jiab477.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/5\/903\/42660160\/jiab477.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/5\/903\/42660160\/jiab477.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T08:29:56Z","timestamp":1646209796000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/225\/5\/903\/6372878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,20]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,9,20]]},"published-print":{"date-parts":[[2022,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab477","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,9,20]]}}}